Information Provided By: 
Fly News Breaks for September 20, 2018
ACAD
Sep 20, 2018 | 13:59 EDT
JPMorgan analyst Cory Kasimov said he views the FDA's statement that "no new or unexpected safety risks" were found upon a review of Nuplazid's safety as a clear positive development that removes a significant overhang on the shares of Acadia. He doesn't expect commercial trends to reverse immediately and Q3 "obviously still matters, but probably not as much after today's news," Kasimov said in a note to investors. He maintains an Overweight rating on Acadia shares.
News For ACAD From the Last 2 Days
There are no results for your query ACAD
